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Abstract			 Alzheimer’s	disease	(AD)	is	characterized	by	two	molecular	pathologies:	cerebral	beta-amyloidosis	(amyloid-beta	[Aβ]	plaques)	and	tauopathy	(neurofibrillary	tangles,	neuritic	plaques	and	neuropil	threads).	Until	recently,	only	Aβ	topographies	could	be	studied	in	vivo	in	humans	owing	to	a	lack	of	tau	positron	emission	tomography	(PET)	imaging	agents.	Current	clinic-pathological	studies	link	tau	pathology	closely	to	the	onset	and	progression	of	cognitive	symptoms	AD.	This	study	reports	on	PET	tau	and	Aβ	imaging	results	in	a	cohort	of	cognitively	normal	older	adults	and	those	with	very	mild	AD.	Multivariate	analyses	identified	unique	disease-related	spatial	topographies	in	both	tau	and	Aβ	deposition.	These	PET	tau	and	Aβ	topographies	were	spatially	unique	but	strongly	related.	Cerebrospinal	fluid	measures	of	tau,	often	used	to	stage	preclinical	AD,	were	strongly	correlated	with	tau	deposition	in	the	temporal	lobe.	Tau	deposition	in	the	temporal	lobe	more	closely	tracked	dementia	status	and	was	a	better	predictor	of	cognitive	performance	than	Aβ	deposition	in	any	region	of	the	brain.	These	data	support	models	of	AD	where	tau	pathology	closely	tracks	changes	in	brain	function	responsible	for	the	onset	of	early	symptoms.		
Introduction	Alzheimer’s	disease	(AD)	is	characterized	neuropathologically	by	the	presence	of	amyloid-beta	(Aβ)	plaques	and	tau-immunoreactive	neuritic	plaques,	neurofibrillary	tangles	and	neuropil	threads	in	the	cerebral	cortex	(1).	Autopsy	studies	demonstrate	that	Aβ	and	tau	pathology	accumulate	in	stereotypical	spatial	
patterns,	or	topographies,	over	the	course	of	the	disease	(2,	3).		Topographic	studies	of	AD-related	pathology	in	vivo,	until	recently,	have	been	limited	to	fibrillar	Aβ (4,	5)	owing	to	a	lack	of	positron	emission	tomography	(PET)	tau	pathology	imaging	agents.	However,	a	number	of	tau	pathology	imaging	agents	have	recently	been	developed	and	are	available	for	human	studies	(6).				 Extant	models	of	AD	pathophysiology	establish	a	temporal	ordering	of	biomarkers,	with	the	emergence	of	AD-related	tauopathy	occurring	downstream	to	the	accrual	of	Aβ	pathology	(7-11).	Consistent	with	this	proposal,	markers	of	tau	pathology	correlate	more	closely	with	changes	in	cognition	compared	to	Aβ measures	(12).		However,	the	prior	lack	of	imaging	agents	has	limited	studies	of	tau	to	post-mortem	examinations	(13-16)	or	measures	that	lack	topographic	information	(i.e.,	cerebrospinal	fluid	[CSF]).	As	a	result,	relationships	between	cognition	and	Aβ	topography	have	been	defined	(17),	but	the	relationship	with	tau	topography	is	not	defined	in	vivo.	Without	this	spatial	information,	CSF	tau	measures	may	be	assessing	other	forms	of	neurodegeneration	related	to	cell	death	or	synaptic	dysfunction.		The	use	of	both	tau	and	Aβ	imaging	allows	for	the	attribution	of	AD-related	cognitive	dysfunction	to	specific	pathological	process	and	locations	within	the	brain.	Further,	the	spatial	relationships	between	tau	pathology	and	other	biomarkers	of	AD	are	not	established.	This	report	examines	how	tau	imaging	topographies	relate	to	clinical	status,	Aβ	imaging,	CSF	measures	of	AD	pathology,	and	
neuropsychological	performance.	Tau	and	Aβ	represent	distinct	pathological	processes	but	they	are	strongly	related	in	the	context	of	AD.	Given	that	PET-	and	CSF-based	techniques	may	measure	similar	processes	(18),	PET	and	CSF	measurements	of	tau	and	Aβ	are	hypothesized	to	be	related	but	that	relationship	is	likely	stronger	within	specific	topographies.	Next,	the	relationship	between	tau	and	Aβ	imaging	with	cognition	was	assessed.	Given	extant	models	(8,	9)	and	limited	autopsy-based	empirical	data	(13-15)	it	was	hypothesized	that	tau	would	be	a	stronger	predictor	of	cognition	than	Aβ	owing	to	its	place	later	in	preclinical	disease	course.	These	relationships	are	investigated	in	vivo	for	the	first	time	using	multivariate	statistical	models	well	suited	to	identify	PET	topographies	associated	with	presence	or	absence	of	disease,	identify	relationships	between	Aβ	and	tau	pathology	in	distinct	topographies,	and	describe	the	relationship	with	CSF	and	neuropsychological	measures	of	disease.		
Results	Data	from	forty-six	individuals	was	examined.	Global	cognitive	and	functional	performance	was	assessed	by	the	clinical	dementia	rating	(CDR)	(19).	Each	participant	underwent	T807	(tau)	(20)	and	florbetapir	(Aβ)	positron	emission	tomography	(PET)	and	magnetic	resonance	imaging	(MRI).	A	subset	also	underwent	lumbar	puncture	for	CSF	assays	and/or	neuropsychological	testing.	Demographics	of	each	subset	of	the	cohort	are	provided	in	Table	1.	Standardized	uptake	value	ratios	(SUVR)	with	(when	presenting	regional	data)	and	without	(when	presenting	voxelwise	data)	partial	volume	correction	were	calculated	within	42	bilateral	
anatomical	regions	of	interest	(ROI)	defined	by	FreeSurfer	(21,	22).	For	additional	methodological	detail	throughout,	see	Methods	and	Supplemental	Material.		Clinically	Impaired	Participants	Demonstrate	Elevated	Tau	Burden	Mean	(across	participants)	tau	and	Aβ	SUVR	images	are	shown	in	Figure	1;	representative	single	subject	data	are	shown	in	Supplemental	Figure	1.	The	data	were	split	into	two	groups	based	on	the	presence	or	absence	of	cognitive	impairment.	Cognitively	normal	(CDR	0;	𝑁 = 36)	participants	show	minimal	tau	tracer	uptake	throughout	the	brain	with	the	exception	of	the	basal	ganglia.	Cognitively	impaired	(CDR>0;	𝑁 = 10)	participants	exhibited	markedly	increased	uptake	in	the	temporal	lobes	and	throughout	the	cortex.	The	Aβ	images	demonstrate	the	known	separation	between	cognitively	normal	and	cognitively	impaired	groups.		Distinct	Tau	and	Aβ	Topographies	are	Associated	with	Cognitive	Impairment	To	assess	the	behavior	of	PET	tau	and	Aβ	pathology	across	participants,	the	imaging	data	were	first	decomposed	into	component	topographies.	This	accomplishes	two	goals:	1)	accounts	for	the	correlation	structure	of	the	data	across	ROIs	and	2)	reduces	the	number	of	statistical	comparisons.	Thus,	singular	value	decomposition	(SVD)	identifies	a	small	number	of	latent	component	topographies	whose	representation	in	single	subjects	explains	a	majority	of	the	variance.	In	each	participant,	PET	tau	and	Aβ	pathology	burden	was	assessed	in	42	ROIs,	however,	many	ROIs	are	highly	correlated	and	can	be	more	concisely	summarized	as	topographies,	or	combinations,	of	ROIs.	The	PET	tau	and	Aβ	data	were	arranged	into	
participant	(N=46)	by	ROI	(M=42)	matrices	separately	and	subjected	to	SVD.	PET	tau	and	Aβ	each	were	best	described	as	a	combination	of	two	component	topographies	(Figure	2A).	Both	PET	tau	and	Aβ	demonstrated	empirically	determined	rank	2	suggesting	that	the	two	biomarkers	have	similar	signal	to	noise	characteristics.	For	both	PET	tau	and	Aβ,	the	first	topography	roughly	corresponded	to	the	mean	of	the	image	(i.e.,	regions	are	similarly	positively	weighted).	The	second	PET	tau	topography	was	most	strongly	loaded	in	the	temporal	lobe	including	the	hippocampus.	In	contrast,	the	second	PET	Aβ	topography	was	most	strongly	loaded	in	frontal	and	parietal	regions.	This	analysis	demonstrates	that	both	PET	tau	and	Aβ	data	exhibit	strong	autocorrelation	across	ROIs	but	each	has	distinct	topographies.			 In	each	participant,	the	representation	of	each	of	the	2	PET	tau	and	2	PET	Aβ	topographies	described	above	was	best	estimated	using	regional	weights	derived	from	the	SVD.	For	each	topography,	these	values	were	subjected	to	an	ANCOVA	with	age,	CDR,	and	presence	of	an	apolipoprotein	(APOE	)	ε4	allele	as	factors	(Supplemental	Table	1).	The	two	PET	tau	topographies	were	more	strongly	represented	in	participants	with	higher	CDR	status	(p	<	0.001)	but	were	not	significantly	modified	by	age	or	APOE	status	(Figure	2B).	The	first	PET	Aβ	topography	was	not	significantly	associated	with	any	variables	of	interest,	however	the	second	topography	was	more	strongly	represented	in	participants	with	higher	CDR	status	(p	=	0.04)	and	moderately	associated	with	increasing	age	(p	=	0.08).	In	both	the	tau	and	Aβ	data	there	are	statistically	significant	differences	between	the	CDR	0	and	CDR>0	groups,	however	there	is	significant	overlap	particularly	in	the	Aβ	
result.	The	separation	between	the	CDR	0	and	CDR>0	groups	was	more	marked	in	the	PET	tau	data	compared	to	the	PET	Aβ	data.	This	visual	observation	is	quantified	as	F	values	that	are	an	order	of	magnitude	larger	for	PET	tau	compared	to	PET	Aβ	(Supplemental	Table	1).	Thus,	as	measured	by	the	CDR,	representation	of	tau	topographies	more	strongly	associates	with	dementia	status	across	participants.		Evidence	of	Preclinical	AD	is	Associated	with	Pathological	Topographies	Inspection	of	Figure	2B	reveals	that	expression	of	the	each	topography	varies	widely	in	the	CDR	0	participants,	particularly	with	respect	to	PET	Aβ	topographies.	CDR	0	implies	cognitive	normality	but	not	absence	of	preclinical	pathology.	Preclinical	AD	can	be	operationalized	using	CSF	measures	of	tau	and	Aβ	with	simple	scalar	cutoffs.	To	most	simply	characterize	the	pathological	status	of	the	CDR	0	participants,	median	splits	were	used	to	dichotomize	participants	as	either	CSF	Aβ±	or	tau±.	Aβ–,	tau–	corresponds	to	healthy	aging	without	pathology;	Aβ+,tau–	corresponds	to	Stage	1	preclinical	disease;	Aβ+,	tau+	corresponds	to	Stage	2	preclinical	disease	(23,	24).		Stratifying	CDR	0	participants	in	this	manner	reveals	that	CDR	0	participants	with	higher	expression	of	the	component	topographies	tend	to	have	CSF	evidence	of	elevated	Aβ	or	tau	pathology	(Figure	2C).	The	effect	of	preclinical	disease	stage	is	more	marked	on	PET	Aβ,	suggesting	that	tau	pathology	burden	is	more	closely	temporally	linked	to	clinical	status	as	measured	by	CDR	and	preclinical	disease	stage.	The	preceding	results	were	reproduced	in	a	larger	sample	who	only	had	PET	tau	data	available	(See	Supplemental	Results).		
PET	Tau	and	Aβ,	in	Distinct	Topographies,	are	Strongly	Correlated		 The	previous	analysis	described	the	relationship	between	PET	tau	and	Aβ	topographies	and	disease	stage.	Next,	the	relationship	between	the	PET	tau	and	Aβ	topographies	was	compared	directly	using	canonical	correlation.	Canonical	correlation	is	a	multivariate	generalization	of	the	more	familiar	bivariate	correlation.	Canonical	correlation	identifies	both	a	PET	tau	and	PET	Aβ	topography	such	that	the	data,	when	projected	onto	these	weighted	topographies,	are	maximally	correlated.	Thus,	canonical	correlation	identifies	the	topography	of	each	pathological	species	that	is	most	related	to	the	other	species.	The	present	PET	tau	and	Aβ	topographies	were	represented	by	a	single	canonical	correlation	that	explained	75%	of	the	covariance	in	the	data	(Figure	3).	The	weighted	regional	patterns	of	the	two	topographies	were	modestly	correlated	(r	=	0.29,	p	=	0.062),	which	reflects	the	known	divergence	in	the	pathologic	topographies	(2,	3).	The	PET	data	weighted	and	averaged	according	to	these	topographies	were	highly	correlated	(r	=	0.92,	p	<	10–18),	which	reflects	the	strong	relationship	between	tau	and	Aβ	when	the	appropriate	topographies	are	considered.	The	PET	tau	topography	that	was	most	heavily	loaded	in	medial	temporal	lobe,	parietal	cortex,	and	precuneus	and	was	most	highly	correlated	with	PET	Aβ	topography	in	the	frontal	and	parietal	regions.		Mean	PET	tau	and	Aβ	are	Correlated	with	CSF	tau,	p-tau,	and	Aβ42	PET	tau	and	Aβ	imaging	techniques	and	CSF	based	techniques	may	measure	correlated	pathological	processes	(18).	Therefore,	the	two	measures	may	be	related.	
To	investigate	this	relationship,	the	correlations	between	mean	(calculated	across	all	grey	matter	regions)	PET	tau	and	Aβ	and	CSF	tau,	phosphorylated	tau	(p-tau),	and	Aβ42	were	calculated	(Supplemental	Table	2).	As	predicted,	mean	PET	tau	was	positively	correlated	with	CSF	tau	(r	=	0.36,	p	=	0.029)	and	CSF	p-tau	(r	=	0.29,	p	=	0.089)	but	was	not	significantly	correlated	with	CSF	Aβ42	(r	=	–0.25,	p	=	0.14);	mean	PET	Aβ	was	negatively	correlated	with	CSF	Aβ42	(r	=	–0.54,	p	=	0.006)	but	also	positively	correlated	with	CSF	tau	(r	=	0.52,	p	=	0.0011)	and	p-tau	(r	=	0.49,	p	=	0.0023).	The	negative	correlations	owe	to	CSF	Aβ42	being	reduced,	not	increased,	by	the	AD	process	as	more	Aβ	becomes	deposited	in	the	brain.	Therefore,	the	PET	and	CSF	techniques	are	strongly	correlated	measures	of	AD	pathological	processes.	However,	the	strengths	of	these	relationships	were	not	remarkably	strong	and	vary	across	biomarkers.	The	limited	strength	of	these	correlations	may	owe	to	the	PET	~	CSF	relationship	only	being	strong	within	particular	topographies;	that	topographic	information	is	necessarily	averaged	across	in	this	analysis.		CSF	Tau	and	Aβ42	are	Correlated	with	Specific	Topographies	of	PET	tau	and	Aβ	Penalized	regression	models	(25-27)	with	either	CSF	tau	or	Aβ42	(separately)	as	an	outcome	and	regional	PET	tau	and	Aβ	SUVR	(together)	as	predictors	were	fit	to	determine	the	relationship	between	CSF	and	regional	PET	measures.	PET	tau	and	Aβ	topographies	were	considered	together	in	the	model	allowing	for	the	data	to	determine	the	modality	that	best	predicted	the	variable	of	interest.	The	critical	feature	of	penalized	regression	is	that	the	solution	is	sparse	(i.e.,	the	regression	βs	corresponding	to	most	PET	tau	and	Aβ	ROIs	are	set	to	zero)	and	only	the	most	
predictive	ROIs	receive	non-zero	regression	β	weights.	The	relationship	between	PET	tau	and	Aβ topographies	and	CSF	tau	was	examined	first.	The	penalized	model	significantly	fit	the	data	(R2	=	0.96;	Z	=	4.72;	p	<	0.0001).	The	combination	of	PET	tau	and	Aβ	topographies	that	best	correlate	with	CSF	tau	are	shown	in	the	top	row	of	Figure	4A	(Exact	values	shown	in	Supplemental	Table	3).	CSF	tau	was	equally	related	to	PET	tau	( 𝛽!"# = 2.93)	and	PET	Aβ	( 𝛽!" = 2.54),	as	measured	by	the	sum	of	the	absolute	value	of	the	regression	β	values	corresponding	to	PET	tau	and	Aβ	ROIs,	respectively.	This	equal	weighting	is	consistent	with	tau	pathology	being	dependent	on	initial	Aβ	accumulation.	Predictive	PET	tau	regions	include	entorhinal	and	temporal	cortex	and	the	cuneus.	The	PET	Aβ	contribution	was	derived	from	temporal	and	frontal	regions.	Similar	topographies	of	predictive	PET	regions	of	interest	were	found	when	predicting	CSF	p-tau;	the	overall	correlation	between	the	CSF	tau	and	CSF	p-tau	predictive	topographies	was	high	(r	=	0.77,	p	<	10-16).				Next,	the	same	relationship	was	investigated	but	with	CSF	Aβ42	as	the	predicted	outcome	variable.	The	penalized	model	significantly	fit	the	data	(R2	=	0.34;	Z	=	3.22;	p	=0.0006).	The	joint	topographies	of	PET	tau	and	Aβ	that	best	correlates	with	CSF	Aβ42	are	shown	in	the	bottom	row	of	Figure	4A	(Exact	values	shown	in	Supplemental	Table	3).	Most	of	the	regression	β	values	are	negative	owing	to	the	inverse	relationship	between	CSF	Aβ	and	pathology	burden.	In	contrast	to	the	CSF	tau	model,	the	predictive	weight	is	more	skewed	towards	PET	Aβ	( 𝛽!" =0.46)	compared	to	PET	tau	( 𝛽!"# = 0.26).		This	suggests	that	PET	tau	has	
relatively	less	predictive	information	relating	to	CSF	Aβ42.	The	contributing	topography	from	PET	tau	was	primarily	loaded	in	the	superior	portions	of	the	cortex.	The	PET	Aβ	topography	is	composed	primarily	of	frontal	and	parietal	regions.	The	highly	significant	predictive	power	of	both	models	suggests	that	there	is	a	strong	relationship	between	CSF	and	PET	measures	of	tau	and	Aβ	pathology.		Specific	tau	and	Aβ	Topographies	Correlate	with	Neuropsychological	Performance	To	examine	the	relationship	between	pathology	and	cognitive	function,	the	relationship	between	PET	tau	and	Aβ	topographies	and	neuropsychological	composite	scores	was	compared	using	the	same	penalized	regression	model	as	described	above.		Each	participant	underwent	neuropsychological	testing	that	is	summarized	into	four	composite	scores	summarizing	the	domains	of	episodic,	semantic,	working	memory,	and	visuospatial	processing	and	an	additional	overall	(global)	measure.	Of	these,	episodic	(Z	=	2.42;	p	=	0.0078),	semantic	(Z	=	4.85;	p	<	0.0001),	visuospatial	(Z	=	5.17;	p	<	0.0001)	and	the	global	score	(Z	=	3.97;	p	<	0.0001)	were	significantly	predicted	by	penalized	regression	after	correction	for	multiple	comparisons	while	the	working	memory	composite	was	not	significantly	fit	by	the	model.	The	combined	PET	tau	and	Aβ	topographies	that	best	predict	each	cognitive	composite	are	shown	in	Figure	4B	(Exact	values	shown	in	Supplemental	Table	3).	In	each	case,	PET	tau	was	the	dominant	topography	with	contributions	to	the	model,	quantified	as	the	sum	of	the	absolute	value	of	the	regression	β,	two-	to	nine-fold	higher	than	the	contribution	of	PET	Aβ.	With	the	exception	of	predicting	episodic	memory,	the	topographies	were	sparse,	including	only	temporal	regions	
and	basal	frontal	regions.	The	overwhelming	contribution	of	PET	tau,	specifically	temporal	lobe	tau,	in	each	tested	domain	demonstrates	that	tau	is	more	closely	related	to	cognition	compared	to	Aβ.	We	further	investigated	the	correlation	between	PET	tau	and	Aβ	topography	and	neuropsychological	composite	scores	in	the	CDR	0	group	only.	In	the	domains	that	were	significantly	associated	with	PET	tau	and	Aβ	topographies	in	the	full	group,	we	refit	the	models	in	the	CDR	0	group	only	and	calculated	the	correlation	between	the	resulting	predictive	topographies.	The	topography	that	was	predictive	of	episodic	memory	scores	in	the	full	group	was	not	correlated	with	predictive	topography	in	the	CDR	0	group	(r	=	0.04,	p	=	0.70).	Similarly,	the	topographies	predictive	of	semantic	memory	performance	were	not	significantly	correlated	(r	=	–0.01,	r	=	0.90).	However,	the	topographies	predicting	visuospatial	performance	(r	=	0.54,	p	<0.001)	and	global	cognitive	performance	(r	=	0.19,	r	=	0.091)	were	correlated,	albeit	the	latter	at	a	trend	level.	These	data	suggest	that	the	relationship	between	pathology	and	neuropsychological	performance	varies	over	the	course	of	the	disease.		
Discussion		 The	present	results	identified	topographies	of	tau	deposition	as	measured	by	T807	PET	that	were	associated	with	clinical	status,	PET	Aβ	deposition,	CSF	AD	biomarkers,	and	AD-related	cognitive	impairment.	A	strong	correlation	existed	between	Aβ	deposited	in	one	topography	and	tau	deposited	in	another	topography.	Tau	imaging,	both	globally	and	in	a	specific	topography,	was	significantly	associated	
with	CSF	measures	of	tau-related	neural	injury.	In	a	combined	model,	PET	tau	deposition	was	demonstrated	to	be	more	closely	associated	with	cognitive	function	than	Aβ	imaging.	Together,	these	results	establish	tau	imaging	as	a	robust	and	important	biomarker	of	AD-related	pathology.		 The	Aβ	imaging	literature	is	vast	and	has	developed	over	more	than	a	decade	(4),	however	tau	imaging	is	a	relatively	new	addition	to	the	field.	FDDNP	was	the	first	tau	imaging	agent	but	had	low	signal	to	noise	properties	and	also	binds	to		Aβ,	which	precluded	investigation	of	specific	pathological	species	(28)	or	required	co-imaging	with	Aβ	agents	and	elaborate	subtraction	procedures	(29).	Methodological	studies	(i.e.,	biochemistry	and	small	animal	studies)	have	identified	several	compounds	that	are	specific	to	tau	pathology	and	possess	favorable	biochemical	properties	(30,	31).	Human	studies	have,	to	date,	have	been	small	(N<25)	and		identified	PET	tau	topographies	consistent	with	post-mortem	studies	(20,	32-35).	In	this	preliminary	body	of	work,	PET	tau	pathology	burden	in	specific	regions	of	interest	(e.g.,	hippocampus)	were	more	strongly	correlated	with	cognitive	performance	and	hippocampal	volume	(34,	35).	These	studies	have	demonstrated	the	utility	of	tau	imaging	agents	in	identifying	tau	pathology	burden	in	vivo.	The	present	study	builds	on	those	studies	by	examining	a	larger	cohort	at	various	disease	stages	and	capitalizing	upon	the	spatial	information	of	PET	by	explicitly	relating	tau	topographies	to	disease	stage,	Aβ	imaging,	CSF	biomarker,	and	cognition.		
	 PET	tau	and	Aβ	imaging	acquires	data	at	the	resolution	of	approximately	5	to	8mm	and	sampled	as	many	thousands	of	voxels,	but	the	true	dimensionality	of	the	data	is	likely	much	lower	(36).	This	study	identified	two	topographies	for	both	PET	tau	and	Aβ	that	explained	most	of	the	variance	in	the	data.	The	two	tau	topographies	were	associated	with	disease	severity	as	measured	by	the	CDR.	The	first	tau	topography	was	homogeneously	distributed	across	the	brain	but	the	second	was	concentrated	in	the	temporal	lobe.	Similarly	the	first	Aβ	topography	was	broadly	distributed	across	the	brain,	while	the	second	Aβ	topography	loaded	more	focally	in	frontal	and	parietal	regions	and	was	significantly	associated	with	disease	stage.	Notably,	the	separation	between	CDR	groups	was	visually	more	marked	with	respect	to	tau	burden	(Figure	2B	and	C),	though	significant	overlap	remains.	Overlap	with	respect	to	CDR	status	likely	represents	the	variable	relationship	between	pathological	burden	and	cognitive	symptoms	often	attributed	to	differences	in	host	factors,	e.g.,	cognitive	reserve	(8,	23).	This	suggests	that	representation	of	pathologically	associated	topographies	of	both	tau	and	Aβ	index	disease	progression	but	the	relationship	to	cognitive	impairment	is	more	pronounced	with	respect	to	tau.				 A	unique	feature	of	AD	is	that	it	is	a	dual	proteinopathy.	Indeed	one	of	the	more	debated	mechanisms	is	how	two	pathological	species	progress	in	independent	topographies	(11,	37,	38).	While	the	topographies	are	distinct,	this	study	uses	canonical	correlation	to	emphasize	that	these	two	processes	are	related.	In	fact,	the	correlation	between	tau	and	Aβ	can	be	remarkably	high	when	the	relevant	
topographies	are	considered.		This	suggests	that,	for	a	given	severity	of	Aβ	deposition,	the	severity	of	tau	pathology	can	also	be	estimated.	The	mechanism	underlying	the	relationship	between	Aβ	and	tau	in	the	generation	of	AD	is	unclear,	but	the	empirical	relationship	is	clearly	evident.			 In	the	absence	of	widely	used	tau	PET	ligands,	CSF-based	measurements	of	tau	pathology	burden	have	predominated	the	AD	field	(39).	CSF-based	measurements	afford	certain	advantages	(e.g.,	broad	applicability)	but	do	not	provide	topographic	information	afforded	by	PET.	Nevertheless,	CSF-based	measures	and	PET-based	measures	index	similar	pathological	processes	in	the	context	of	AD.	As	a	result,	a	high	correlation	between	mean	PET	tau	SUVR	and	CSF	tau	is	expected.	Perhaps	less	intuitive,	but	commonly	observed,	is	the	strong	relationship	between	CSF	tau	and	PET	Aβ	SUVR,	even	in	the	absence	of	neurofibrillary	tangles	(40).	This	relationship	could	be	understood	in	terms	of	the	ordered	nature	of	biomarker	progression;	once	detectable	tau	pathology	is	present	there	is	already	advanced	Aβ	pathology,	allowing	for	a	significant	relationship	(8,	9).	More	importantly,	the	relationship	between	CSF	and	PET	derived	measures	were	topographically	specific.		The	specificity	of	this	relationship	strengthens	the	argument	that	the	identified	relationships	are	disease	specific:	elevated	tau	in	the	CSF	is	associated	with	tau	deposition	within	regions	known	to	be	sensitive	to	AD-related	tauopathy	(2).	Taken	together,	these	lines	of	evidence	suggest	that	the	desired	pathological	process	is	being	measured	by	both	techniques.		
	 Understanding	the	contribution	of	tau	and	Aβ	to	cognitive	symptoms,	particularly	early	in	AD,	has	been	restricted	owing	to	the	lack	of	topographic	tau	information	in	vivo.	In	this	study,	the	predictive	power	of	PET	tau	and	Aβ	topographies	on	neuropsychological	performance	was	evaluated.	In	each	investigated	cognitive	domain,	the	weight	assigned	to	PET	tau	in	the	best	fitting	model	was	larger	than	the	weight	assigned	to	PET	Aβ.	This	implies	that	tau	burden,	not	Aβ	burden,	is	more	closely	linked	to	cognition.	This	increased	correlation	suggests	that	tau	and	cognition	are	more	closely	linked,	consistent	with	extant	models	of	AD	(8,	9).	Further,	PET	imaging	data	coupled	with	the	present	penalized	regression	approach	also	provides	regional	specificity.	Temporal	lobe	tau	tended	to	be	the	strongest	predictor	of	cognitive	performance	consistent	with	known	focus	of	tau	pathology.	The	selective	nature	of	the	present	models	suggests	that	tauopathy	severity	in	the	temporal	lobe	is	sufficient	to	predict	cognitive	impairment	across	the	early	disease	stages	investigated	here.			 Taken	together,	these	data	provide	important	insight	into	the	relationship	between	tau	topographies	and	other	measures	of	AD	pathology	and	cognitive	symptoms.	This	inference	is	made	possible	by	the	emergence	of	PET	tau	imaging	agents.	Tau	imaging	accurately	discriminates	disease	stage	assessed	by	the	CDR,	strongly	correlates	with	CSF	measures,	in	particular	within	temporal	regions,	and	is	more	related	to	cognitive	performance	than	Aβ	imaging.	Thus,	tau	pathology	appears	to	be	more	closely	linked	to	cognitive	dysfunction	consistent	with	existing	hypotheses.	These	data	suggest	distinct	roles	of	PET	Aβ	and	tau	imaging	going	
forward.	PET	Aβ	will	likely	remain	a	powerful	tool	for	early	detection	of	AD	pathology	during	the	preclinical	period.	However,	these	data	suggest	a	close	relationship	between	PET	tau	and	disease	stage	and	symptomatology	will	be	critical	for	tracking	the	efficacy	of	disease	modifying	therapies.		
Materials	and	Methods	Study	Design	Forty-six	participants	were	recruited	from	ongoing	studies	of	memory	and	aging	at	the	Knight	Alzheimer	Disease	Research	Center	at	Washington	University	in	St	Louis.	Participants	underwent	cognitive	assessment	with	the	clinical	dementia	rating	(CDR)	(19),	MRI	and	PET	imaging	with	T807	and	Florbetapir.	All	participants	with	CDR>0	(i.e.,	clinically	impaired)	carried	clinical	diagnoses	of	Alzheimer’s	disease	or	mild	cognitive	impairment	due	to	Alzheimer’s	disease.	A	subset	of	participants	also	underwent	lumbar	puncture	(N=36)	and	neuropsychological	assessment	(N=40).	All	participants	or	their	designees	provided	written	informed	consent	prior	to	participating	in	this	study	that	was	consistent	with	the	regulations	of	the	Washington	University	in	St	Louis	School	of	Medicine	Institutional	Review	Board.		Neuropsychological	Assessment	A	comprehensive	neuropsychological	battery	was	administered	to	all	participants,	typically	within	two	weeks	of	the	annual	clinical	assessment.		Standardized	test	scores	were	averaged	to	form	four	composites	[see	
(41)	for	details	on	construction	of	composites	and	the	standardization	sample].		The	episodic	memory	composite	included	the	sum	of	the	three	free	recall	trials	from	the	Selective	Reminding	Test	(42),	Associate	Learning	from	the	Wechsler	Memory	Scale	(WMS)	(43),	and	immediate	recall	of	the	WMS	Logical	Memory	or	Wechsler	Memory	Scale-Revised	(WMS-R)	(44)	Logical	Memory.		The	semantic	composite	included	the	Information	subtest	from	the	Wechsler	Adult	Intelligence	Scale	(WAIS)	(45),	the	Boston	Naming	Test	(46),	and	Animal	Naming	(46).		The	working	memory	composite	included	WMS	Mental	Control,	Digit	Span	Forward	and	Digit	Span	Backward,	and	Letter	Fluency	for	S	and	P.	The	visuospatial	composite	included	the	WAIS	Block	Design	and	Digit	Symbol	subtests	and	Trailmaking	Test	A	and	B	(47).		Imaging	MRI	and	florbetapir	data	were	acquired	on	a	Biograph	mMR	scanner	(Siemens	Medical	Solutions,	Erlangen,	Germany)	in	a	single	session.	T807	data	were	acquired	in	a	separate	session	on	a	Biograph	40	PET/CT	scanner.	Participants	received	a	single	intravenous	(IV)	bolus	injection	of	10	mCi	of	florbetapir	and	a	single	IV	bolus	injection	of	6.5-10	mCi	of	T807.	PET	data	were	analyzed	using	our	standard	technique	(18,	19)	implemented	in	the	PET	unified	pipeline	(http://github.com/ysu001/PUP).	FreeSurfer	segmentation	(44)	(http://freesurfer.net/)	was	used	as	the	basis	of	the	quantitative	analysis	to	obtain	regional	standardized	uptake	value	ratio	(SUVR)	with	cerebellar	gray	matter	as	the	reference	region.	Partial	volume	correction	was	also	performed	using	a	regional	spread	function	(RSF)	technique	(19).	For	florbetapir	PET,	the	data	
between	50-70	minutes	post-injection	were	used	for	the	analysis;	and	for	T807,	the	imaging	data	between	80-100	minutes	were	used	instead.		CSF	Analysis	CSF	(20-30	mL)	was	collected	after	overnight	fasting	as	described	previously	(48,	49).	Total	and	phosphorylated	tau	and	Aβ42	were	measured	using	ELISA	(INNOTEST;	Fujirebio,	formerly	Innogenetics,	Ghent,	Belgium).		Dimensionality	Reduction	and	Analysis	of	a	Single	PET	Modality	PET	SUVR,	for	both	T807	and	Florbetapir,	can	be	measured	at	the	resolution	of	voxels,	structurally	or	functionally	defined	sets	of	voxels,	or	the	entire	brain.	This	gives	rise	to	datasets	that	appear	to	be	high	dimensional	(i.e.,	many	samples	per	imaging	session)	but	can	be	represented	by	lower	dimensional	projections.	These	bases	can	be	identified	using	singular	value	decomposition	(SVD)	or	related	procedures	(e.g.,	principal	component	analysis).	In	PET	data,	these	composite	factors	represent	topographies	(i.e.,	the	weighted	combination	of	brain	regions)	and	the	contribution	of	a	given	topography	to	an	individual	participant’s	data	can	be	estimated.	SVD	was	performed	on	the	regional	SUVR	values	(as	variables)	across	participants	(as	samples)	for	tau	and	Aβ	separately.	The	number	of	significant	factors	was	determined	by	a	permutation	test.		Identifying	the	Relationship	Between	Tau	and	Aβ	Topographies	and	CSF	and	Neuropsychological	Performance	Using	Penalized	Regression	
Penalized	regression	was	used	to	identify	the	relationship	between	CSF	tau	and	Aβ42	or	neuropsychological	Z	scores,	as	outcome	variables,	and	PET	tau	and	Aβ	topographies	(as	predictors).	The	penalty	in	penalized	regression	is	enforced	against	the	estimated	regression	βs	(26).	The	family	of	penalized	regression	fit	here	is	the	elastic-net	penalty	(27):	the	L1	penalty	component	enforces	sparsity	(i.e.,	many	βs	will	be	identically	0,	not	included	in	the	model)	(26)	while	the	L2	penalty	allows	highly	correlated	variables	to	enter	the	model	simultaneously	(27).	Elastic-net	models	are	well	suited	for	data	that	are	highly	collinear	such	as	regional	PET	data.	Model	parameters	(total	penalty	and	relative	contribution	of	L1	and	L2	penalty)	are	chosen	by	cross-validation.	Penalized	regression	models,	like	any	machine	learning	algorithm,	are	prone	to	overfitting.	To	assess	significance	of	the	fit	models,	permutation	resampling	determined	the	distribution	of	R2	values	under	the	null	hypothesis.	 		Canonical	Correlation	Identifies	Relationships	Between	Tau	and	Aβ	Topographies		 Description	of	the	correlation	between	tau	and	Aβ	topographies	is	accomplished	using	canonical	correlation	(50,	51).	Canonical	correlation	is	the	multivariate	generalization	of	the	more	familiar,	e.g.,	Pearson	bivariate	correlation.	Canonical	correlation	identifies	the	weighted	average	of	ROIs	in	one	distribution	that	is	maximally	correlated	with	another	weighted	average	of	ROIs	in	another	distribution.	The	weighting	vectors,	or	canonical	vectors,	define	topographies.		 	
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Table	1.	Study	Cohort	Demographics.		 T807	+	Florbetapir	 T807	+	Florbetapir	+	CSF	 T807	+	Florbetapir	+	NP	N	 46	 36	 40	Age	(standard	deviation)	 75.4	(6.6)	 76.3	(6.6)	 75.7	(6.5)	M/F	 30	/	16	 25	/	11	 27	/	13	CDR	0/0.5/≥1	 36	/	7	/	3	 31	/	2	/	3	 34	/	4	/	2	APOE	ε4+	 20	 16	 18	Demographics	for	the	main	cohort	and	two	subsets.	CSF=cerebrospinal	fluid	assay,	NP=	Neuropsychological	Testing.	APOE=	apolipoprotein	ε	
	 	
Figures	and	Figure	Captions	
	Figure	1.	Mean	positron	emission	tomography	(PET)	tau	and	Aβ	topographies	in	participants	with	and	without	clinical	Alzheimer’s	disease	(AD).	Mean	tau	SUVR	images	averaged	across	participants	with	clinical	dementia	rating	(CDR)	0	(top	row)	or	CDR>0	(bottom	row).	Images	are	presented	in	radiological	convention.		 	
	Figure	2.	PET	tau	and	Aβ	topographies	are	associated	with	disease	severity.	A:	Right	singular	vectors	(𝑉)	of	the	singular	value	decomposition	(SVD)	of	the	regional	PET	tau	and	Aβ	data	represented	as	topographies.	The	dimensionality	of	both	tau	and	Aβ	was	estimated	to	be	two.	The	first	topography	for	both	PET	species	broadly	represents	the	mean	(i.e.,	all	regions	are	homogeneously	weighted).	The	second	tau	topography	is	present	within	the	temporal	lobe	and	the	second	Aβ	topography	is	largely	seen	in	frontal	and	parietal	lobes.	Color	bar	represents	regional	weights	within	each	singular	component.	B:	The	representations	of	these	topographies	in	individuals	(left	singular	vectors;	𝑈),	or	put	another	way,	the	data	original	data	projected	onto	these	topographies,	varies	with	CDR	for	both	PET	tau	topographies	
and	the	second	PET	Aβ	topography.	Increasing	disease	severity	(measured	using	the	CDR)	is	associated	with	increasing	representation	of	the	present	topographies	in	individuals.	However,	particularly	in	the	Aβ	data,	there	is	significant	heterogeneity.	
C:	Similar	graphs	as	(B)	but	only	participants	with	CSF	are	included.	Color	in	the	CDR	0	group	indicates	preclinical	disease	status.	Blue	corresponds	to	healthy	aging	(i.e.,	no	Aβ	or	tau	pathology),	green	corresponds	to	Stage	1,	red	corresponds	to	Stage	2.		 	
	Figure	3.	Tau	and	Aβ	in	distinct	topographies	are	strongly	correlated.	A:	Topographies	for	PET	tau	and	PET	Aβ	derived	from	canonical	correlations	that	maximize	the	correlation	between	PET	tau	and	Aβ	deposition.	B:	Scatter	plot	of	the	weights	on	each	region	demonstrates	that	PET	tau	and	Aβ	topographies	are	not	
significantly	related.	This	is	consistent	with	the	typical	topographies	of	tau	and	Aβ	pathology	being	distinct.	C:	The	data	projected	onto	the	canonical	variables	however	reveals	a	robust	positive	relationship.		 	
	Figure	4:	CSF	and	Neuropsychological	Performance	are	predicted	by	tau	and	Aβ	Topographies.	Each	row	represents	a	single	penalized	regression	model	where	either	CSF	protein	levels	or	neuropsychological	performance	is	predicted.		 𝛽!"# 	and	 𝛽!" 	represent	the	total	predictive	weight	of	tau	and	Aβ	topographies,	respectively.	Grey	regions	have	no	predictive	weight.	A:	Penalized	regression	models	that	predict	CSF	tau	and	Aβ42	using	tau	and	Aβ	topographies.	As	CSF	Aβ42	levels	are	inversely	related	to	amyloid	burden,	negative	weights	indicate	regions	where	topographies	predict	worse	CSF	Aβ42	pathology.	B:	Penalized	regression	
models	that	predict	neuropsychological	performance.	Regions	with	negative	values	are	where	more	PET	pathology	predicts	lower	cognitive	performance.		
